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a b s t r aC t
since 2007, the netherlands is faced with the largest 
outbreak of q fever ever reported. in the last four 
years, over 4000 cases have been reported. the course 
of the epidemic and possible factors associated with 
this sudden surge in cases of q fever is described and 
the preventive measures in the veterinary sector and 
the outbreak management of this unique epidemic are 
summarised. finally, the latest data on clinical presentation 
and diagnostic and therapeutic dilemmas of q fever in the 
netherlands are reviewed.
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i n t roduC t i on
Since 2007, the Netherlands is faced with the world’s 
largest outbreak of Q fever with over 4000 notified 
cases. Q fever is caused by Coxiella burnetii, a small, 
Gram-negative obligate intracellular bacterium, 
phylogenetically related to Legionellales. Transmission 
occurs through inhalation of infected aerosols. The 
reservoir consists mainly of dairy goats and sheep, but 
excretion of Coxiella has also been described in other cattle 
and rodents. Small outbreaks associated with parturient 
pets such as cats and dogs have also been reported.1 The 
animals shed the bacterium in urine and faeces, and in 
very high concentrations in birth by-products. C. burnetii 
is extremely infectious as was illustrated by an experiment 
demonstrating that inhalation of a single bacterium could 
cause seroconversion in humans.2 It was classified as a 
category B bioterrorism agent.
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f e v e r  i n  t h e  n e t h e r l a nd s
The epidemic in the Netherlands is concentrated in 
the southern part of the country, in the provinces of 
Brabant, Gelderland and Limburg, although increasing 
numbers are being reported from the Northern provinces. 
A seroprevalence study performed on samples that were 
collected in a national immunisation survey in 2006 
(PIENTER-2) showed a low seropositivity rate for Q fever of 
2.4% just before the outbreak, indicating that the epidemic 
in 2007 was indeed newly emerging and did not merely 
reflect heightened awareness of physicians for Q fever.3
Already in 2007, an association with intense goat farming 
in the region was suggested.4 In 2008, a large human 
cluster of Q fever in an urban area was clearly linked to 
a dairy goat farm with a Q fever related abortion episode 
a few weeks before the first human cases presented.5 The 
high relative risk (31.1 [95% CI 16.4 to 59.1]) to contract 
Q fever when living within a 2 km radius of a dairy goat 
farm compared with persons living more than 5 km 
away supported this hypothesis.5 Although most cases 
seem to be related to dairy farming, transmission from 
non-dairy sheep has also been described in a small 
epidemic of at least 28 cases among patients and staff of a 
psychiatric institution.6 Besides proximity to urbanisation, 
multiple other environmental factors are involved in the 
transmission of Q fever from infected farms. Hunink 
and colleagues showed a correlation between higher 
vegetation density and higher groundwater levels and lower 
transmission of Q fever from infected farms in various 
regions in the Netherlands.7 Since Coxiella is extremely 
resistant to heat and desiccation, it can survive in the 
environment for many months. 
Outbreaks of this magnitude are unprecedented. Recent 
European outbreaks in Germany and Switzerland 
were limited to a short epidemic without significant 
recurrences in the following years.8,9 Up until 2007, 
an average of 20 cases of human Q fever were reported 
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yearly in the Netherlands. The reason for the surge in 
clinical problems in humans and animals is still unclear. 
Possible explanations include the increase of the dairy goat 
population (from 5000 in 1985 to over 375,000 in 2009). 
Moreover, the type of goat husbandry has changed with 
sometimes up to thousands of animals in one dairy farm. 
In contrast to other countries experiencing smaller Q 
fever epidemics, in the Netherlands these farms are often 
located in highly populated areas. 
After the first year of the epidemic in the Netherlands 
(with 168 confirmed cases), a limited number of preventive 
measures were taken. However in 2008, there was a 
further increase in the number of reported human cases 
in the Netherlands. Preventive regulations implemented 
in autumn 2008 consisted of making Q fever a notifiable 
disease for the veterinary sector (for humans it has been 
notifiable since 1978), prohibiting the spread of manure 
from infected farms, and compulsory vaccination for all 
non-pregnant goats on dairy goat farms in the region. 
Although vaccination does not eliminate the disease, 
it is effective in reducing massive bacterial shedding 
from a heavily infected herd, thereby limiting the risk of 
environmental contamination.10 Before 2010, however, 
there was a considerable shortage of veterinary vaccine 
and vaccination of all goats was not possible. Therefore, 
after the further increase in human cases in 2009 (by 
then with multiple reports of fatal cases, especially of 
chronic Q fever), drastic measures were taken. Farms were 
tested by means of polymerase chain reaction testing for 
Coxiella on bulk milk, and culling of more than 50,000 
goats on 88 infected farms was started in December 2009. 
Furthermore, breeding on those farms was prohibited. 
Inhabitants of the area within 5 km of the contaminated 
farms were alerted regarding possible Q fever. A list of 
positive farms was made available to the public (http://
www.vwa.nl/onderwerpen/dierziekten/dossier/q-koorts/
kaart-met-overzicht-van-besmette-bedrijven). In 2010, 
fewer cases of Q fever have been reported compared with 
2009. Although differences in weather circumstances 
could play a role in this decrease, it seems that the 
measures taken have had a positive effect on limiting 
transmission to humans. 
C l i n i C a l  a s p e C t s  o f  q  f e v e r
acute q fever
Acute Q fever occurs two to six weeks after exposure 
depending on the infective dose. The infection remains 
asymptomatic in up to 60% of patients. Patients with 
symptomatic disease usually present with fever and mild 
flu-like symptoms. Because these symptoms are very 
non-specific, under-reporting is probably quite substantial. 
A case-control study investigating the first outbreak of Q 
fever in the Netherlands in 2007 showed that all patients 
with symptomatic infection experienced fever.11 Headache 
and cough were reported by 92 and 85%, respectively. 
Smoking was found to be an important risk factor, as 
had been shown by others previously.12,13 Male sex has 
also been identified as a risk factor for symptomatic 
disease.14 In 2007 and 2008, the female-to-male ratio 
of acute Q fever was 1:1.7.15 The mean age was 51 years. 
Although hospitalisation rates of 2% have been described 
in literature, hospital admission was much more frequent 
in the Netherlands. In 2007, almost 50% of Q fever cases 
were admitted.11 This high percentage could have been 
influenced by active case finding in a retrospective study 
among hospitalised patients. In the subsequent years, 
admission rates stabilised to around 20%, still considerably 
higher than reported in literature.16
Chronic q fever
Chronic Q fever develops in 1 to 2% of patients after 
acute Q fever. Some patients with chronic Q fever do not 
recall having had an acute infection.17 It usually develops 
insidiously, months or even years after acute infection 
and patients often present with non-specific symptoms 
such as low-grade fever, night sweats and weight loss. In 
a large retrospective study from France, endocarditis was 
found to be the predominant manifestation of chronic Q 
fever, constituting 73% of chronic Q fever cases. Other 
manifestations were vascular infection (8%), chronic 
infection in pregnancy (6%), and chronic hepatitis (3%).18 
In the Netherlands however, a substantially higher 
percentage of chronic Q fever cases consists of patients 
with infected aneurysms and vascular prostheses. In a 
recent report, 12 out of 22 chronic Q fever patients in 
the Netherlands had vascular infection.19 Four of these 
patients were diagnosed by screening 52 patients with 
an aortic aneurysm. The authors advocate screening all 
patients with symptomatic aortic aneurysms in a highly 
endemic region for chronic Q fever. Chronic Q fever is not 
systematically reported to the national health authorities in 
the Netherlands. It is estimated that around 40 to 50 cases 
of chronic Q fever have been diagnosed in the Netherlands 
in the past three years. Up to half of these cases have 
vascular infection. A nationwide database on chronic Q 
fever will be established to collect these data and facilitate 
epidemiological research.
q fever and pregnancy
Literature on chronic Q fever during pregnancy is limited. 
A case series of 53 pregnant women diagnosed with Q 
fever showed obstetric complications in 81% of patients 
not treated with long-term cotrimoxazole therapy compared 
with 44% in patients who did receive cotrimoxazole.20 An 
important pitfall in this observational study, as indicated 
by the authors, is the fact that serology for Q fever was 
Delsing, et al. Q fever in the Netherlands.
384
d e c emb e r  2 0 1 0 ,  v o l .  6 8 ,  n o  1 2
performed only after delivery in 28% of patients, often 
because of obstetric complications, creating a selection 
bias. Interpretation of these results is therefore difficult. 
Two large seroprevalence studies found no significant 
association between seropositivity for Coxiella and adverse 
pregnancy outcome.21,22 A study among pregnant women 
in the area of the first outbreak in the Netherlands in 
2007 showed evidence of recent infection in three out of 
19 women (16%). This was significantly higher than in the 
surrounding regions.23 A retrospective study in the highly 
endemic area in the southern part of the Netherlands 
showed no significant correlation of seropositivity for 
Q fever during early pregnancy and adverse pregnancy 
outcome.16 To further investigate the effect of Q fever on 
pregnancy, a randomised controlled trial was started in the 
spring of 2010 evaluating the effect of a screen and treat 
policy of pregnant women in this area. 
post q fever fatigue syndrome
Following acute Q fever, patients frequently report a 
long-lasting and debilitating fatigue. A study performed 
after an outbreak of acute Q fever in the United Kingdom 
showed 20% of patients suffered from chronic fatigue 
syndrome after ten years of follow-up, compared with 
4% of controls.24 A study among abattoir employees in 
Australia showed that 28% of patients with proven acute 
Q fever still fulfilled the CDC criteria of chronic fatigue 
syndrome at five years after infection compared with none 
of seronegative controls.25 A case-control study among 54 
patients who contracted acute Q fever in the first year of 
the epidemic in the Netherlands showed that after one 
year, over 50% still reported severe fatigue compared 
with 26% of controls.26 The aetiology of this severe 
fatigue, referred to as QFS (Q fever Fatigue Syndrome), 
still remains to be elucidated. Cytokine dysregulation 
resulting from chronic immune stimulation and 
modulation by persistence of Coxiella or its antigens has 
been hypothesised.27 Genotyping of patients suffering 
from QFS showed significant differences in HLA-DRB1*11 
and interferon-γ intron 1 microsatellite compared with 
controls.28,29 Some reports suggest persistence of Coxiella 
or antigenic non-viable cell residues in bone marrow.30,31 
Studies evaluating antibiotic treatment for QFS have shown 
conflicting results.32,33 QFS leads to considerable morbidity 
and a high socioeconomic burden related to increased use 
of healthcare facilities and absence from work. 
d i agnos i s  o f  q  f e v e r
Analysis of specimens from various infected dairy 
farms has shown that 14 different strains circulate in 
the Netherlands, but one is predominantly present in 
the highly endemic area (Roest HJ, unpublished data). 
Isolation of Coxiella from blood culture specimens of 
Q fever patients is difficult since it is an obligatory 
intracellular organism. In addition, chronic infection 
often resides in tissues (e.g., heart valves or vascular 
aneurysms) and shedding into peripheral blood occurs 
in very low concentrations. Culture of Coxiella requires 
very specific procedures and a biosafety level 3 laboratory, 
which is not available to most hospitals. Until now, culture 
of the pathogen has been successful in only one patient in 
the Netherlands, in whom Coxiella was cultured from a 
resected heart valve (Roest HJ, personal communication).
Diagnosis of acute Q fever is based on serology, the 
reference method being immunofluorescence assay (IFA). 
A seroconversion of a fourfold rise in antibody titre is 
diagnostic for acute Q fever.34 An important drawback in 
diagnosis based on serology is that antibody production 
does not usually occur until a few weeks after onset of 
clinical symptoms. PCR on serum has been shown to have 
a high sensitivity (98%) for acute Q fever in seronegative 
patients and is a useful diagnostic tool for early diagnosis.35 
An algorithm for the diagnosis of acute Q fever in the 
Netherlands, designed by the Dutch working group on 
diagnostics of acute Q fever (an initiative of the National 
Institute for Public Health and the Environment (RIVM) 
and the Dutch Association for Medical Microbiology), 
has been published very recently.36 There has been a 
substantial reduction of the diagnostic delay in the 
Netherlands from 82 days in 2007 to 20 days in 2009.37 
Because treatment has to be started before laboratory 
confirmation, physicians have to rely on clinical signs to 
guide the decision to start empiric therapy for Q fever. 
Antibiotic treatment of community acquired pneumonia 
in a high endemic region should include an agent active 
against Coxiella burnetii.38
Diagnosis of chronic Q fever remains difficult. Because 
the infection persists intracellularly, PCR on peripheral 
blood is not always positive. Imaging techniques can be 
useful to localise infection. Infected aneurysms or vascular 
prostheses can be identified by 18F-fluorodexyglucose 
(FDG) positron emission tomography (PET) or CT. In case 
of endocarditis, however, diagnosis is often more complex. 
The original Duke criteria developed for diagnosing 
infective endocarditis include vegetations and positive 
blood cultures as major criteria. However, vegetations are 
often absent in Q fever endocarditis18 and as mentioned 
above, Coxiella does not grow in conventional blood culture 
media. Therefore a revision of the Duke criteria has been 
proposed in which a serological profile compatible with 
chronic Q fever has been added to the major criteria.39 
Serology is therefore an important tool in the evaluation 
of the development of chronic disease. Coxiella burnetii 
displays a unique antigenic variance in surface 
polysaccharides (phase 1 and phase 2 antigens). This can 
be used to distinguish between acute and chronic infection. 
Delsing, et al. Q fever in the Netherlands.
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In acute infection, mainly phase 2 antibodies develop and 
convalescent sera show low titres of phase 1 antibodies, 
whereas chronic infection is characterised by high titres 
of phase 1 antibodies. Most literature on determination 
of cut-off values for establishing the diagnosis of chronic 
Q fever originates from the French National Reference 
Centre for Rickettsial Diseases (NRC) and this group has 
proposed a cut-off value for IgG to phase 1 proteins of 
1:800 for the diagnosis of chronic Q fever.40 This cut-off 
value was also adopted by the revised Duke criteria.39 In the 
Netherlands, however, a substantial percentage of patients 
showed much higher titres of IgG1 during the first months 
after acute infection. There seems to be a considerable 
difference between the serological method used in the 
Netherlands (Focus diagnostics) and the method used in 
the NRC in France. This was recently illustrated by a case 
report of serological follow-up after acute Q fever, which 
showed high titres to IgG1 comparable with those found in 
Dutch patients but much lower when tested in the NRC in 
France.41 In 2009, a provisional guideline was published in 
the Netherlands proposing a new cut-off value for IgG1 of 
1:4096 (or an IgG1 equal to IgG2) (www.medischcontact.
artsennet.nl). However, when using this algorithm, 40% 
of patients with proven chronic Q fever (signs and or 
symptoms compatible with chronic Q fever and persistently 
positive PCR on blood or positive PCR on resected valves 
or aneurysms) who presented at the Radboud Expertise 
Centre for Q fever do not fulfil these criteria (table 1). The 
Netherlands Society for Medical Microbiology (NVMM) is 
currently developing a new guideline for the diagnosis of 
chronic Q fever in the Netherlands.
t r e at M en t  o f  q  f e v e r
Comparative trials regarding the optimal antibiotic 
treatment for acute Q fever are sparse, often retrospective 
and sometimes show conflicting results. Doxycycline is 
the preferred choice, but the new-generation quinolones 
such as moxifloxacin are also active against C. burnetii.42 
Clarithromycin has also been shown to be effective43 and 
co-trimoxazole is the treatment of choice in children younger 
than 8 years of age.44 Although the national guidelines for 
treating community acquired pneumonia (CAP) issued 
by the Dutch Working Party on Antibiotic Policy (SWAB) 
and the Dutch College of General Practitioners (NHG) 
recommend doxycycline for first-line treatment of CAP, the 
alternative regimens in these guidelines do not routinely 
cover C. burnetii. Nevertheless, most general practitioners 
in the highly endemic region are aware of this problem and 
treat their patients with either doxycycline or moxifloxacin.45 
A survey among general practitioners in this region showed 
that 95% would consider Q fever as a possible pathogen when 
suspecting a pneumonia and would start empiric treatment 
with doxycycline.46 The move away from doxycycline in the 
proposed update of the NHG guidelines for treatment of 
pneumonia by general practitioners seems inappropriate 
for endemic regions and may lead to increased numbers of 
chronic infections.
The optimal treatment of chronic Q fever consists of 
doxycycline and hydroxychloroquine.47 The latter increases 
the intralysosomal pH and thereby achieves a bactericidal 
effect in vitro when combined with doxycycline, whereas 
doxycycline alone is only bacteriostatic.48 Based on a 
retrospective study, a minimum duration of 18 months 
of combination therapy has been recommended with 
target levels of doxycycline of 5 mg/l.47 This long-term 
therapy is associated with significant adverse effects 
and photosensitisation has been described in 100% of 
patients on long-term therapy.47 Other frequently reported 
side effects include nausea, headache and dizziness. 
Regular evaluation by an ophthalmologist is recommended 
because of possible irreversible maculopathy due to 
hydroxychloroquine. Maintaining optimal adherence to 
therapy therefore requires intensive counselling and 
therapeutic drug monitoring.
Delsing, et al. Q fever in the Netherlands.
table 1. Clinical and microbiological data from 10 patients with chronic Q fever presented to the Radboud Expertise 
Centre for Q fever
patient localisation of 
infection
igg1 titre at 
diagnosis
igg2 titre at 
diagnosis
pCr q fever blood pCr q fever tissue
M, 75 y Endocarditis 8192 32768 Positive NA
M, 62 y Aneurysm 2048 4096 Negative Positive
M, 69 y Endocarditis 65536 65536 Positive Positive
M, 69 y Endocarditis 16384 16384 Positive NA
M, 57 y Aneurysm 1024 4096 Negative Positive
M, 68 y Aneurysm 4096 4096 Negative Positive
M, 75 y Endocarditis >4096 >4096 Positive NA
M, 62 y Aneurysm 1024 >4096 Positive NA
M, 67 y Aneurysm 2048 2048 Positive NA
F, 60 y Unknown 8192 4096 Negative NA
386
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pr e v e n t i on  o f  q  f e v e r  i n  huM a ns
The preventive measures taken in the veterinary sector 
have been aimed at reducing the spread of C. burnetii in 
the environment and thereby limiting the transmission 
to humans. Human vaccination is a different approach 
in preventing Q fever in individuals with a high risk of 
exposure to Coxiella. An effective whole-cell vaccine is 
available in Australia and has been extensively used in 
persons with high occupational risks such as abattoir 
employees. In this population, it has been proven to be 
highly effective.49 Because administering this vaccine to 
patients with pre-existing immunity increases the risk of 
local and systemic inflammatory reactions, prior infection 
needs to be excluded by skin testing and serology. Recently, 
the Health Council of the Netherlands issued an advice on 
vaccinating patients with increased risk of chronic Q fever 
with this whole cell vaccine (http://www.gezondheidsraad.
nl/nl/adviezen/vaccinatie-van-mensen-tegen-q-koorts-
eerste-advies). The target population has been defined 
as patients with underlying cardiac conditions (the same 
category of patients who would also qualify for endocarditis 
prophylaxis according to current guidelines), as well as 
patients with a known (aortic) aneurysm or vascular 
prosthesis.
Since Q fever is highly endemic in the southern part of the 
Netherlands and infection can be asymptomatic, there is 
a possible risk of transmission through blood transfusion. 
Preliminary results indicate that in 2009 C. burnetii DNA 
was present in a small percentage of blood donations in 
this area (indicated by positive PCR on donated blood).16,50 
Sanquin, the Dutch blood supply foundation, has instituted 
screening of donated blood in the high-incidence area as a 
precautionary measure.
ConC lus i on
Although it appears that the epidemic of Q fever in 
the Netherlands is now subsiding, physicians are still 
faced with growing numbers of patients suffering from 
long-term sequelae of Q fever such as chronic infection and 
Q fever fatigue syndrome. Optimal management of these 
conditions is still unclear and further research is needed to 
improve diagnostic strategies, to evaluate treatment, and to 
prevent chronic infections.
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